Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Swedbank AB

Swedbank AB lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 780,486 shares of the medical research company's stock after selling 189,026 shares during the period. Swedbank AB owned approximately 0.13% of Edwards Lifesciences worth $57,779,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after purchasing an additional 273 shares during the period. Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after acquiring an additional 300,000 shares during the period. Avanza Fonder AB purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $4,845,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company's stock worth $31,571,000 after purchasing an additional 40,348 shares during the period. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on EW shares. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Truist Financial reissued a "hold" rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an "overweight" rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $79.19.

Edwards Lifesciences Price Performance

EW traded up $2.29 during midday trading on Thursday, hitting $73.42. 1,940,481 shares of the company traded hands, compared to its average volume of 4,602,016. The business has a 50 day simple moving average of $72.40 and a two-hundred day simple moving average of $70.07. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market capitalization of $43.30 billion, a price-to-earnings ratio of 10.61, a PEG ratio of 3.54 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.